From the Department of Cardiovascular Medicine (H.W., H.A., C.R.) and the Wellcome Trust Centre for Human Genetics (H.W.), University of Oxford, Oxford, United Kingdom.
Supported by the British Heart Foundation Centre of Excellence at Oxford, Wellcome Trust, European Commission Framework Programme Grant (241577), and Oxford Partners National Institute for Health Research Comprehensive Biomedical Research Centre.
Dr. Watkins reports being listed as a patent holder on patents held by Harvard University for methods for detecting disease-associated mutations in hypertrophic cardiomyopathy; and Dr. Ashrafian reports holding a European method-of-use patent for perhexiline in systolic heart failure and having patents pending for its use in diastolic heart failure and hypertrophic cardiomyopathy and for its use in systolic heart failure in countries outside Europe.
We thank Dr. Mary Sheppard, Royal Brompton Hospital, London, for the histologic images and Dr. Theodoros Karamitsos and Professor Stefan Neubauer, University of Oxford, Oxford, United Kingdom, for the cardiac magnetic resonance images.
